In Re Relafen Antitrust Litigation

States sued manufacturer of antidepressant Relafen, alleging patent misuse and sham litigation designed to prevent generic entry. Parties settled the state proprietary claims for $10 million.

Read More →

Maryland v. SmithKline Beecham Corp., No. 2:06-cv-01298-JP (E.D.Pa Mar. 27, 2006)

States sued manufacturer of antitdepressant Paxil, alleging patent misuse and sham litigation designed to prevent generic entry. Parties settled for $14 million.

Read More →

Connecticut v. Mylan Laboratories, Inc. (In re Lorazepam & Clorazepate Antitrust Litigation), MDL No. 1290 (D.D.C. June 15, 2000) 205 F.R.D. 369 (D.D.C. 2002); No. 98 CV 3115 (D.D.C. 2000) – complaint

Plaintiff States alleged that Mylan Laboratories, Inc.(Mylan) and other drug companies entered into illegal agreements to monopolize the market for certain generic anti-anxiety drugs.

Read More →

New York v. Microsoft Corp., 97 F. Supp. 2d 59 (D.D.C. 2000)

U.S. Department of Justice and the Plaintiff States alleged that the Defendant, Microsoft Corporation violated State and Federal law by maintaining a monopoly in the market for Intel-compatible personal computer operating systems and by illegally tying its Windows operating system to its Internet Explorer browser.

Read More →

Texas v. Conoco, Inc. and Phillips Petroleum Company (D.C. TX, 2002); Missouri v. Conoco Inc., No. 02-4190-CV-W-NKC (W.D. Mo. Oct. 2,

Plaintiff States sought to enjoin Conoco, Inc. (Conoco) and Phillips Petroleum Company (Phillips Petroleum) from consummating their merger, arguing that the merger would significantly impair competition for natural gas gathering and for natural gas liquids fractionation.

Read More →

Texas v. Zeneca, 1997 U.S. Dist. LEXIS 13153 (N.D. Tex. 1997)

States sought an injunction and monetary damages from Zeneca, Inc. (Zeneca), alleging that the company conspired with distributors of its crop protection chemicals to maintain the resale price of the chemicals.

Read More →

In re Compact Disc Minimum Advertised Price Antitrust Litigation MDL No. 1361 (D. Me. 2002) MDL-1391; No. 00-CIV-5853 (BSJ) (S.D.N.Y Aug. 8, 2000) (complaint)

Plaintiff States sought damages and injunctive relief, alleging that Defendant CD distributors unlawfully conspired to implement stringent minimum advertised price (MAP) policies in violation of antitrust laws.

Read More →

In re: Buspirone Antitrust Litigation,Case No. 01 CV 11401, MDL 1410, MDL 1413 (S .D.N.Y.) (see also Ohio v. Bristol Myers Squibb

Plaintiff States sought damages and injunctive relief, alleging that Bristol-Myers Squibb Co. (BMS) attempted to maintain an unlawful monopoly on buspirone hydrochloride, a medication used to treat generalized anxiety. In settling, BMS agreed to a stipulated injunction and to reimburse consumers and state and local public entities for overcharges. In 2008, plaintiff states sued BMS for failing to report accurately to the states, pursuant to the settlement, a patent arrangement involving the drug Plavix. The company pleaded guilty to lying to the FTC and the states recovered $1.1 million in fines.

Read More →

In re Cardizem CD Antitrust Litigation 99-MD-1278 (E.D. Mich. Jan. 29, 2003), 332 F.3d 896 (6th Cir. 2003)

Plaintiff States sought damages and injunctive relief, alleging that defendants entered into an unlawful agreement attempting to delay or prevent the marketing of less expensive generic alternatives to Cardizem CD, a brand name drug used to prevent heart attacks. The Plaintiff States settled for $80 million, the bulk of which was to be used to reimburse purchasers including consumers, insurance companies and other third-party payers for overcharges paid for Cardizem CD between 1998 and 2003.

Read More →

Maryland et al v. Mitsubishi Electronics America; 1992-1 Trade Cas. (CCH) ¶69,743 (D. Md. 1992)

Plaintiff States sought damages and injunctive relief, alleging that Mitsubishi Electronics America, Inc. (MELA) conspired with its dealers to set or maintain the resale price of its electronics equipment. In the settlement with Plaintiff States, MELA was enjoined from engaging in the alleged conduct and agreed to pay $6 million dollars for administrative costs and to reimburse qualified buyers.

Read More →